BioNTech Shareholder Revolt Meets Strategic Overhaul as Founders Prepare Their Exit

Investor Bernd Förtsch seeks the removal of BioNTech's founding couple over Arife conflicts, as the biotech cuts three German sites and shifts to oncology.

A prominent BioNTech investor is publicly calling for the removal of the company's founding couple, sharpening a governance dispute just as the Mainz-based biotech group executes one of the most sweeping restructurings in its history.

Bernd Förtsch, who holds stakes in both BioNTech and rival Moderna, wants Ugur ?ahin and Özlem Türeci to step down over potential conflicts of interest tied to Arife, the mRNA venture the two are preparing to launch. At issue is an unresolved agreement on how patents and operating assets will be divided between the old company and the new one. That deal was supposed to be settled by June 30. It still isn't — yet ?ahin and Türeci intend to get Arife off the ground by December 31. Förtsch is pressing for a swift resolution and an independent valuation of the assets in question.

He backs his argument with BioNTech's balance sheet. The group sits on EUR 16.6 billion in cash, which in Förtsch's calculation leaves roughly EUR 5.2 billion for the operating business once the money is stripped out.

A painful exit from pandemic-era manufacturing

The governance fight lands against a backdrop of deep operational cuts. BioNTech plans to shut three German production sites — Idar-Oberstein, Marburg and Tübingen — phasing them out through the end of 2028 after failing to find buyers for the facilities. COVID-19 vaccine output is being handed over entirely to long-time US partner Pfizer. As many as 1,860 positions are affected, with socially acceptable arrangements negotiated with the works council.

Tübingen's mayor, Boris Palmer, has publicly disputed the company's account, suggesting the closures were planned from the start. For BioNTech, the retreat marks a return to its roots: the sprawling industrial capacity was a wartime necessity during the pandemic, but in a world of fading demand those factory halls turned into a costly burden. By shedding capital-intensive mass production, the group is transforming back into what it was before the global spotlight — a research-driven development shop that channels its funds into clinical work rather than expensive infrastructure.

Founders chart a separate course

The shake-up reaches all the way to the top. According to media reports, co-founders ?ahin and Türeci have established Arife, a company focused on next-generation mRNA medicines, and will leave BioNTech by the end of 2026. ?ahin's sale of personal share packages under a pre-arranged trading plan — executed a little over a week ago, with the stock up 0.5% since — fits the picture of a transition. Such transactions naturally stir psychological reservations among market participants.

The strategic question underneath it all: can the organization make the leap from a founder-led exception to an institutionalized pharmaceutical company? Without the charismatic research duo at the helm, the remaining pipeline has to prove it can stand on its own.

Oncology data carries the story

That proof is being sought in the cancer studies. Roughly two weeks ago, BioNTech presented updated Phase 3 data for the antibody Gotistobart in cooperation with OncoC4: median overall survival in pretreated squamous non-small cell lung cancer reached 18.5 months versus 10.0 months on docetaxel chemotherapy. The decisive second stage of the registration trial continues.

Meanwhile, a Phase 2 setback hit the pipeline when the colon cancer study of BNT122 with partner Genentech was discontinued. Other clinical projects are moving ahead, including BNT113 for HPV16-positive head and neck cancer and BNT116 against non-small cell lung cancer. The mRNA therapy landscape remains dynamic, with competitors such as Moderna and Merck advancing on positive Phase 3 melanoma results.

Markets take the upheaval in stride

For all the turbulence, investors have shown remarkable calm. The stock closed yesterday at EUR 87.00, up 7.0% since the start of the year — the feared meltdown after vaccine revenue faded has not materialized. On Thursday, however, the shares slipped 1.1% to EUR 86.05 as the dispute over Arife weighed on sentiment. Sector observers describe the leadership fight as a significant burden at an awkward moment: unresolved intellectual property allocation ties up valuable management time and complicates a clear strategic positioning against competitors.

BioNTech still rests on a solid financial foundation, with a market capitalization of EUR 21.95 billion. How quickly management brings clarity to Arife will shape what comes next. Shareholders want a transparent solution so the focus can return fully to the oncology pipeline — because from here on, the fate of the stock will be decided not on the production lines of Hesse or Baden-Württemberg, but in the labs and cancer centers.